In our study, the CDKN2A/2B deletion accounted for 25.5% of the whole cohort (22.3% among B-ALL cases), with the prevalence of the deletion rising to 51.8% when evaluated within the T-ALL subgroup. Here, CDKN2A is linked to acute lymphoblastic leukemia.